Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital of Crete
The combination of FOLFOXIRI plus cetuximab is reasonable safe regimen especially for patients with good performance status. The estimated benefit from the combination is greater than the possible risk, especially for the patients who will become resectable after treatment. It will be extremely interesting to evaluate the resectability rate of this specific group of patient with good performance status and unresectable disease when they are treated with all active chemotherapeutic agents and cetuximab
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically proven metastatic adenocarcinoma of the colon or rectum
Patients with operable metastatic disease are excluded from the study
Age 18-70 years
Performance status (ECOG) 0-1
At least one bidimensionally measurable lesion of \>= 2cm
Creatinine and total bilirubin \< 1.25 times the upper limit of normal
Aspartate and alanine aminotransferase \< 3.0 times the upper limit of normal (\<5 times in case of liver mets)
You may not be if
Absence of active infection or malnutrition (loss of more than 20% of the body weight)
No history of a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma. curatively treated
Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields.
Patients with severe cardiac dysfunction, liver metastases involving more than 50% of the liver parenchyma, chronic diarrhea, or prior irradiation affecting more than 30% of the active bone marrow are excluded.
All patients will have to sign written informed consent in order to participate in the study
Clareo Health | Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
